At the third session of PHEN’s 20th Annual African American Prostate Cancer Disparity Summit, top representatives from the pharmaceutical sector participated in a panel discussion about the industry perspective on making prostate cancer a chronic condition. The panelists included:
- Geeta Devgan, PhD, Prostate Cancer Team Lead in US Medical Affairs at Pfizer
- Robert Bridwell, MD, Medical Advisor at the Sofie Company
- Jay Jhaveri, MD, MPH, Medical Director in US Medical Affairs – Oncology Managing Prostate Cancer at Bayer
- Alessandra Cesano, MD, PhD, Chief Medical Officer and Executive Vice President at Essa Pharma
- Peter Francis, MD, MBA, Global Medical Affairs Lead for Early Prostate Cancer at Johnson & Johnson
The panelists discussed what each of their biopharmaceutical companies have been developing, such as hormonal therapies, to ensure prostate cancer becomes a treatable, chronic disease instead of a life-threatening one.
“Hope is the word of the day. There are so many things that are available [to treat prostate cancer],” said Dr. Jay Jhaveri. “We’re in the Renaissance of prostate cancer [treatments].”
phen,
Leave a Reply